Nadunolimab combined with chemotherapy showed no significant efficacy improvement in metastatic TNBC, despite surpassing ...

The phase 3 MajesTEC-3 trial demonstrated that the combination of the bispecific BCMA-directed T-cell engager teclistamab and ...

Patients receiving Pola-R-CHP were found to be more likely to be male (58% vs 54%), younger (mean age, 75.0 vs 77.5 years), ...

A recently cleared phase 3 study (NCT06051409) will evaluate olverembatinib combined with chemotherapy as a first-line ...

Explore the advantages and challenges of long-term red blood cell transfusions for low-risk MDS patients, focusing on quality ...

Red blood cell transfusions enhance quality of life for MDS patients but require careful management to avoid complications ...

Early results from the OLYMPIA-3 trial reveal odronextamab plus CHOP chemotherapy shows promising efficacy for untreated ...

Robert Orlowski, MD, PhD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses prophylactic ...

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks ...

Exploring the impact of inflammation in MDS, this article highlights the need for novel therapies to enhance patient quality ...

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks ...

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks ...